Effects of Nutrition on Post Stroke Fatigue
A legfontosabb adatok
- Hol
- Roma (Olaszország)A helyszín megnézése
AI-kivonat: kiket keres a vizsgálat
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
A vizsgálat olyan embereket keres, akiknek 1–6 hónapja volt agyi történése (stroke-ja), és tudnak járni. Azt vizsgálja, hogy a SiderAL® Med táplálékkiegészítő csökkenti-e a fáradtságot, és segít-e a mozgásban és a gondolkodásban.
- Életkor
- A rekord két különböző korhatárt ad meg: a feltételekben legalább 5 év, a rekord fejlécében pedig legalább 55 év.
- Nem
- Minden nem részt vehet.
- A betegség stádiuma
- Iszkémiás vagy vérzéses stroke, amelyet agyi képalkotás (MR vagy CT) igazol, és a stroke óta 1–6 hónap telt el.
- Korábbi kezelés
- Nem szedhet napi 3000 NE-nél több D-vitamint. Nem kaphat K-vitamin-antagonista kezelést.
- Biomarker vagy leletérték
- Token Test pontszám legalább 26.5, vagyis képes követni az egyszerű utasításokat.
A részvétel fő kizáró okai
- Túl sok elektrolit a vérben
- Anyagcsere-eredetű ásványianyag-raktározási betegség (például hemochromatosis, Wilson-kór)
- Dialízis kezelésben lévők
- Szív-, ideg- vagy az egész testet érintő betegség, amely a járást veszélyessé teszi vagy mozgászavart okoz
- Daganatos betegség
Gépi kiolvasás: 2026. november 12.
Helyszínek itt: Olaszország
- Fondazione Policlinico Universitario A. Gemelli IRCCSRoma, OlaszországContact: Silvia Giovannini, MD, phDRésztvevőt keres
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakA vizsgálat adatai
- Ki végzi
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
- Azonosító
- NCT05728229
- A regiszteradat frissítve
- 2025. július 14.
- Eredeti leírás
Fatigue, which is commonly defined as a feeling of tiredness during or after usual activities, or a feeling of insufficient energy to initiate these activities, is one of the most common secondary conditions among patients presenting with stroke.A teljes eredeti leírásKevesebb
Effetti Della Nutrizione Sulla Fatica Post Stroke
Fatigue, which is commonly defined as a feeling of tiredness during or after usual activities, or a feeling of insufficient energy to initiate these activities, is one of the most common secondary conditions among patients presenting with stroke.
Post Stroke Fatigue (PSF) is a multidimensional motor-perceptual, emotional, and cognitive experience characterized by a feeling of early exhaustion with tiredness, lack of energy, and difficulty making efforts, which develops during physical or mental activities, and usually does not improve with rest.
To try to counteract fatigue and its effects on daily life activities, in addition to the known pharmacological approach (Modafinil), the use of vitamins and minerals is known to mitigate, among others, the effects of fatigue. Nutrients provide the energy needed to maintain the body's structural and biochemical integrity. Energy is associated with a feeling of well-being, increased stamina and vitality which often translates into the ability to undertake daily physical or cognitive activities and social relationships, as opposed to fatigue.
A common feature of fatigue is a "sense of energy exhaustion" which can objectively be related to not enough energy. Physical and cognitive tiredness occurs when the continuous demand for energy from the brain and muscles is not met. In humans, dietary macronutrients provide the fuel needed, among other things, to perform physical activity. In fact, mineral salts and vitamins are essential for the production of cellular energy, for the maintenance of brain structures and for allowing the formation of intercellular connections.
When the intake of vitamins and mineral salts is adequate, their biochemical properties translate into normal physiological functions; a lower intake of mineral salts and vitamins is associated with lethargy and physical and cognitive fatigue. However, few studies have evaluated the effect of vitamin and mineral supplementation for the management of physical and cognitive fatigue.
SiderAL® Med is a food for Special Medical Purposes (AFMS), with a complete formulation that contains vitamins, sucrosomial minerals (Iron, Iodine, Magnesium, Zinc and Selenium), copper and algal calcium, with enhanced dosages to meet particular needs nutritional. AFMS are products formulated for the dietary management of patients with proven nutritional needs, for whom modifications to the normal diet are not sufficient.
In some cases, these are subjects with limited, disturbed or altered ability to take, digest, absorb, metabolize or eliminate certain nutrients, in other cases, however, nutritional needs can be determined by specific clinical conditions.
On the basis of scientific evidences, therefore, the aim of the study is to evaluate whether the nutritional supplement with SiderAL® Med improves the symptom of fatigue, motor and cognitive function in patients with stroke outcomes.
Bevonási feltételek: Age greater than or equal to 5 years; Patients with ischemic or haemorrhagic stroke outcomes documented through neuroimaging techniques (magnetic resonance or computed tomography); Latency from the acute event between 1 and 6 months; Cognitive skills that allow you to carry out simple orders and understand the physiotherapist's instructions [assessed through the Token Test (score ≥ 26.5)]; Ability to walk independently or with little assistance; Ability to understand and sign informed consent.
Kizáró feltételek: Therapy with Vitamin K antagonists; Conditions causing excess electrolytes in the blood; Diagnosis of metabolic mineral storage disorders (eg, hemochromatosis, Wilson); Systemic, neurological, cardiac pathologies that make walking risky or cause motor deficits; Vitamin D intake greater than 3000 IU/day; Dialysis patients; Oncological pathologies; Problems of an orthopedic or postural nature; Presence of plantar ulcers; Partial or total amputation of segments of the foot; Inability to provide informed consent.